Hiroki Wada
AstraZeneca
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Hiroki Wada.
Journal of Medicinal Chemistry | 2010
Ayumu Kurimoto; Kazuki Hashimoto; Tomoaki Nakamura; Kei Norimura; Haruhisa Ogita; Haruo Takaku; Roger Victor Bonnert; Tom McInally; Hiroki Wada; Yoshiaki Isobe
Systemic administration of a Toll-like receptor 7 (TLR7) agonist is effective to in suppressing Th2 derived inflammation, however systemic induction of various cytokines such as IL-6, IL-12, and type I interferon (IFN) is observed. This cytokine induction would be expected to cause flu-like symptoms. We have previously reported adenine compounds (3, 4) as interferon inducing agents acting as TLR7 agonists. To identify potent anti-inflammatory compounds without systemic side effects, a labile carboxylic ester as an antedrug functionality onto the N(9)-benzyl group of the adenine was introduced. We found that 9e was a potent TLR7 agonist (EC(50) 50 nM) and rapidly metabolized by human plasma (T(1/2) 2.6 min) to the pharmacologically much less active carboxylic acid 16. Intratracheal administration of 9e effectively inhibited allergen-induced airway inflammation without inducing cytokines systemically. Therefore, the TLR7 agonist with antedrug characteristics 9e (SM-324405) is a novel candidate for immunotherapy of allergic diseases.
Toxicology and Applied Pharmacology | 2013
Peter Stewart Gilmour; Patrick J. O'Shea; Malbinder Fagura; James Pilling; Hitesh Sanganee; Hiroki Wada; Paul Courtney; Stefan Kavanagh; Peter A. Hall; K. Jane Escott
Wnt activation by inhibiting glycogen synthase kinase 3 (GSK-3) causes bone anabolism in rodents making GSK-3 a potential therapeutic target for osteoporotic and osteolytic metastatic bone disease. To understand the wnt pathway related to human disease translation, the ability of 3 potent inhibitors of GSK-3 (AZD2858, AR79, AZ13282107) to 1) drive osteoblast differentiation and mineralisation using human adipose-derived stem cells (hADSC) in vitro; and 2) stimulate rat bone formation in vivo was investigated. Bone anabolism/resorption was determined using clinically relevant serum biomarkers as indicators of bone turnover and bone formation assessed in femurs by histopathology and pQCT/μCT imaging. GSK-3 inhibitors caused β-catenin stabilisation in human and rat mesenchymal stem cells, stimulated hADSC commitment towards osteoblasts and osteogenic mineralisation in vitro. AZD2858 produced time-dependent changes in serum bone turnover biomarkers and increased bone mass over 28 days exposure in rats. After 7 days, AZD2858, AR79 or AZ13282107 exposure increased the bone formation biomarker P1NP, and reduced the resorption biomarker TRAcP-5b, indicating increased bone anabolism and reduced resorption in rats. This biomarker profile was differentiated from anabolic agent PTH1-34 or the anti-resorptive Alendronate-induced changes. Increased bone formation in cortical and cancellous bone as assessed by femur histopathology supported biomarker changes. 14 day AR79 treatment increased bone mineral density and trabecular thickness, and decreased trabecular number and connectivity assessed by pQCT/μCT. GSK-3 inhibition caused hADSC osteoblastogenesis and mineralisation in vitro. Increased femur bone mass associated with changes in bone turnover biomarkers confirmed in vivo bone formation and indicated uncoupling of bone formation and resorption.
Journal of Medicinal Chemistry | 2018
Cristina Gardelli; Hiroki Wada; Asim Ray; Moya Caffrey; Antonio Llinas; Igor Shamovsky; Joakim Tholander; Joakim Larsson; Ulf Sivars; Leif Hultin; Ulf Andersson; Hitesh Sanganee; Kristina Stenvall; Brith Leidvik; Karin Gedda; Lisa Jinton; Marie Rydén Landergren; Kostas Karabelas
Cachexia and muscle wasting are very common among patients suffering from cancer, chronic obstructive pulmonary disease, and other chronic diseases. Ghrelin stimulates growth hormone secretion via the ghrelin receptor, which subsequently leads to increase of IGF-1 plasma levels. The activation of the GH/IGF-1 axis leads to an increase of muscle mass and functional capacity. Ghrelin further acts on inflammation, appetite, and adipogenesis and for this reason was considered an important target to address catabolic conditions. We report the synthesis and properties of an indane based series of ghrelin receptor full agonists; they have been shown to generate a sustained increase of IGF-1 levels in dog and have been thoroughly investigated with respect to their functional activity.
Archive | 2005
Ayumu Kurimoto; Kazuki Hashimoto; Yoshiaki Isobe; Stephen Brough; Ian Millichip; Hiroki Wada; Roger Victor Bonnert; Thomas Mcinally
Tetrahedron Letters | 2012
Hiroki Wada; Lili Cheng; Ji Jiang; Zhigan Jiang; Jun Xie; Tao Hu; Hitesh Sanganee; Tim Luker
Archive | 2017
Hiroki Wada; Roger Victor Bonnert; Stephen Thom; Thomas Mcinally
Archive | 2008
Roger Victor Bonnert; Thomas Mcinally; Stephen Thom; Hiroki Wada
Archive | 2008
Roger Victor Bonnert; Thomas Mcinally; Stephen Thom; Hiroki Wada
Archive | 2007
Anthony Ronald Cook; Tom McInally; Stephen Thom; Hiroki Wada
Archive | 2006
Thomas Mcinally; Stephen Thom; Hiroki Wada